141 related articles for article (PubMed ID: 33811491)
1. Population pharmacokinetic model of subcutaneous fentanyl in older acute care patients.
Al-Qurain AA; Upton R; Williams DB; Mackenzie L; Phillips C; Russell PT; Tadros R; Roberts MS; Wiese MD
Eur J Clin Pharmacol; 2021 Sep; 77(9):1357-1368. PubMed ID: 33811491
[TBL] [Abstract][Full Text] [Related]
2. Population Pharmacokinetic Model for Tramadol and O-desmethyltramadol in Older Patients.
Al-Qurain AA; Upton RN; Tadros R; Roberts MS; Wiese MD
Eur J Drug Metab Pharmacokinet; 2022 May; 47(3):387-402. PubMed ID: 35167052
[TBL] [Abstract][Full Text] [Related]
3. Treatment with subcutaneous and transdermal fentanyl: results from a population pharmacokinetic study in cancer patients.
Oosten AW; Abrantes JA; Jönsson S; de Bruijn P; Kuip EJ; Falcão A; van der Rijt CC; Mathijssen RH
Eur J Clin Pharmacol; 2016 Apr; 72(4):459-67. PubMed ID: 26762381
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetic meta-analysis of intranasal fentanyl spray as a means to enrich pharmacokinetic information for patients with cancer breakthrough pain.
Kaessner N; Nave R; Roepcke S; Facius A; Lahu G
Int J Clin Pharmacol Ther; 2012 Sep; 50(9):665-77. PubMed ID: 22784611
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of subcutaneous fentanyl in Greyhounds.
KuKanich B
Vet J; 2011 Nov; 190(2):e140-e142. PubMed ID: 21388844
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and pharmacodynamics of intranasal versus intravenous fentanyl in patients with pain after oral surgery.
Foster D; Upton R; Christrup L; Popper L
Ann Pharmacother; 2008 Oct; 42(10):1380-7. PubMed ID: 18728103
[TBL] [Abstract][Full Text] [Related]
7. Factors Contributing to Fentanyl Pharmacokinetic Variability Among Diagnostically Diverse Critically Ill Children.
Hagos FT; Horvat CM; Au AK; Conley YP; Li L; Poloyac SM; Kochanek PM; Clark RSB; Empey PE
Clin Pharmacokinet; 2019 Dec; 58(12):1567-1576. PubMed ID: 31168770
[TBL] [Abstract][Full Text] [Related]
8. A predictive pharmacokinetic/pharmacodynamic model of fentanyl for analgesia/sedation in neonates based on a semi-physiologic approach.
Encinas E; Calvo R; Lukas JC; Vozmediano V; Rodriguez M; Suarez E
Paediatr Drugs; 2013 Jun; 15(3):247-57. PubMed ID: 23657896
[TBL] [Abstract][Full Text] [Related]
9. Exposure to Fentanyl After Transdermal Patch Administration for Cancer Pain Management.
Bista SR; Haywood A; Hardy J; Norris R; Hennig S
J Clin Pharmacol; 2016 Jun; 56(6):705-13. PubMed ID: 26381285
[TBL] [Abstract][Full Text] [Related]
10. An innovative phase I population pharmacokinetic approach to investigate the pharmacokinetics of an intranasal fentanyl spray in healthy subjects.
Plock N; Facius A; Hartmann L; Baumann S; Nave R
Int J Clin Pharmacol Ther; 2013 Jun; 51(6):495-508. PubMed ID: 23611571
[TBL] [Abstract][Full Text] [Related]
11. Inter- and intraindividual variabilities in pharmacokinetics of fentanyl after repeated 72-hour transdermal applications in cancer pain patients.
Solassol I; Bressolle F; Caumette L; Garcia F; Poujol S; Culine S; Pinguet F
Ther Drug Monit; 2005 Aug; 27(4):491-8. PubMed ID: 16044107
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetic analysis for hydrocodone following the administration of hydrocodone bitartrate extended-release capsules.
Melhem MR; Rubino CM; Farr SJ; Robinson CY
Clin Pharmacokinet; 2013 Oct; 52(10):907-17. PubMed ID: 23719682
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of fentanyl in male and female rats after intravenous administration.
Ohtsuka H; Fujita K; Kobayashi H
Arzneimittelforschung; 2007; 57(5):260-3. PubMed ID: 17598696
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics meta-analysis of recombinant human erythropoietin in healthy subjects.
Olsson-Gisleskog P; Jacqmin P; Perez-Ruixo JJ
Clin Pharmacokinet; 2007; 46(2):159-73. PubMed ID: 17253886
[TBL] [Abstract][Full Text] [Related]
15. Characterizing Fentanyl Variability Using Population Pharmacokinetics in Pediatric Burn Patients.
Grimsrud KN; Lima KM; Tran NK; Palmieri TL
J Burn Care Res; 2020 Jan; 41(1):8-14. PubMed ID: 31538188
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of intravenous and transdermal fentanyl in alpacas.
Lovasz M; Aarnes TK; Hubbell JAE; Bednarski RM; Lerche P; Lakritz J
J Vet Pharmacol Ther; 2017 Dec; 40(6):663-669. PubMed ID: 28317124
[TBL] [Abstract][Full Text] [Related]
17. Multiple dose pharmacokinetics of oral transmucosal fentanyl citrate in healthy volunteers.
Egan TD; Sharma A; Ashburn MA; Kievit J; Pace NL; Streisand JB
Anesthesiology; 2000 Mar; 92(3):665-73. PubMed ID: 10719944
[TBL] [Abstract][Full Text] [Related]
18. Formulation selection and pharmacokinetic comparison of fentanyl buccal soluble film with oral transmucosal fentanyl citrate: a randomized, open-label, single-dose, crossover study.
Vasisht N; Gever LN; Tagarro I; Finn AL
Clin Drug Investig; 2009; 29(10):647-54. PubMed ID: 19715381
[TBL] [Abstract][Full Text] [Related]
19. Plasma Concentrations of Fentanyl Achieved With Transdermal Application in Chickens.
Delaski KM; Gehring R; Heffron BT; Negrusz A; Gamble KC
J Avian Med Surg; 2017 Mar; 31(1):6-15. PubMed ID: 28358614
[TBL] [Abstract][Full Text] [Related]
20. Prolonged therapy with the anticonvulsant carbamazepine leads to increased plasma clearance of fentanyl.
Nozari A; Akeju O; Mirzakhani H; Eskandar E; Ma Z; Hossain MA; Wang Q; Greenblatt DJ; Martyn JAJ
J Pharm Pharmacol; 2019 Jun; 71(6):982-987. PubMed ID: 30793320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
